Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health

Exclusion Criteria

• •Any abnormality preventing reliable applanation tonometry in the study eye(s).
• •Presence of any ocular pathology in either eye seen during the slit lamp or fundus exams, that in the opinion of the Investigator may preclude the safe administration of test article or safe participation in this study.
• •Dry eye or keratoconjunctivitis sicca (KCS) which has been, or is currently being, treated with the use of punctal plugs, punctal cautery, Restasis®, or topical ocular corticosteroids.
• •Patients who have undergone keratorefractive ocular laser procedures, corneal surgery or surgery to the corneal surface, including but not limited to LASIK and PRK, within 6 months prior to Visit 1.
• •Patients who have undergone intraocular or extra-ocular surgery, in either eye, within 6 months prior to Visit 1.
• •Any history of ocular infections or inflammatory ocular conditions within the past 3 months in either eye.
• •Use of any systemic medications on a chronic basis that have not been on a stable dosing regimen for at least 30 days prior to Visit 1.
• •Use of ocular medications other than XALATAN® within 7 days of Visit 1.
• •Use of corticosteroids within 30 days of Visit 1.
• •Use of contact lenses within 30 days of Visit 1. Concomitant use of contact lenses is also excluded for the duration of the study.
• •History of intolerance or hypersensitivity to any component of the test articles.
• •Participation in an investigational drug or device study within 30 days of entering this study.
• •History or evidence of corneal transplant or transplant variant procedures.